Combination therapy using GDNF and cell transplant in Parkinson's disease.

Publication Year: 2022

DOI:
10.1186/s13024-022-00553-9

PMCID:
PMC9288671

PMID:
35842673

Journal Information

Full Title: Mol Neurodegener

Abbreviation: Mol Neurodegener

Country: Unknown

Publisher: Unknown

Language: N/A

Publication Details

Subject Category: Molecular Biology

Available in Europe PMC: Yes

Available in PMC: Yes

PDF Available: No

Transparency Score
3/6
50.0% Transparent
Transparency Indicators
Click on green indicators to view evidence text
Core Indicators
Data Sharing
Code Sharing
Evidence found in paper:

"Declarations Ethics approval and consent to participateNot applicable. Consent for publicationNot applicable. Competing interestsS‐C.Z. is the co‐founder of BrainXell, Inc. Competing interests S‐C.Z. is the co‐founder of BrainXell, Inc."

Evidence found in paper:

"Funding The authors are supported by National Medical Research Council (STaR and PD-LCG 0002 SPARKS II programme to TEK, CS-IRG-NIG and OF-YIRG to XB)."

Protocol Registration
Open Access
Paper is freely available to read
Additional Indicators
Replication
Novelty Statement
Assessment Info

Tool: rtransparent

OST Version: N/A

Last Updated: Aug 05, 2025